206 related articles for article (PubMed ID: 19276202)
1. Role of the stem domain of matriptase in the interaction with its physiological inhibitor, hepatocyte growth factor activator inhibitor type I.
Kojima K; Tsuzuki S; Fushiki T; Inouye K
J Biochem; 2009 Jun; 145(6):783-90. PubMed ID: 19276202
[TBL] [Abstract][Full Text] [Related]
2. Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.
Inouye K; Tsuzuki S; Yasumoto M; Kojima K; Mochida S; Fushiki T
J Biol Chem; 2010 Oct; 285(43):33394-33403. PubMed ID: 20682770
[TBL] [Abstract][Full Text] [Related]
3. The optimal activity of a pseudozymogen form of recombinant matriptase under the mildly acidic pH and low ionic strength conditions.
Inouye K; Yasumoto M; Tsuzuki S; Mochida S; Fushiki T
J Biochem; 2010 Apr; 147(4):485-92. PubMed ID: 19919953
[TBL] [Abstract][Full Text] [Related]
4. Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase.
Kojima K; Tsuzuki S; Fushiki T; Inouye K
J Biol Chem; 2008 Feb; 283(5):2478-87. PubMed ID: 18048349
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
6. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
7. The activity of a type II transmembrane serine protease, matriptase, is dependent solely on the catalytic domain.
Kojima K; Tsuzuki S; Fushiki T; Inouye K
Biosci Biotechnol Biochem; 2009 Feb; 73(2):454-6. PubMed ID: 19202271
[TBL] [Abstract][Full Text] [Related]
8. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
Eigenbrot C; Ganesan R; Kirchhofer D
FEBS J; 2010 May; 277(10):2215-22. PubMed ID: 20402765
[TBL] [Abstract][Full Text] [Related]
10. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
11. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
12. Activation of a membrane-bound serine protease matriptase on the cell surface.
Miyake Y; Yasumoto M; Tsuzuki S; Fushiki T; Inouye K
J Biochem; 2009 Aug; 146(2):273-82. PubMed ID: 19398443
[TBL] [Abstract][Full Text] [Related]
13. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
[TBL] [Abstract][Full Text] [Related]
14. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase.
Larsen BR; Steffensen SD; Nielsen NV; Friis S; Godiksen S; Bornholdt J; Soendergaard C; Nonboe AW; Andersen MN; Poulsen SS; Szabo R; Bugge TH; Lin CY; Skovbjerg H; Jensen JK; Vogel LK
Exp Cell Res; 2013 Apr; 319(6):918-29. PubMed ID: 23333561
[TBL] [Abstract][Full Text] [Related]
16. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
[TBL] [Abstract][Full Text] [Related]
17. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides.
Béliveau F; Désilets A; Leduc R
FEBS J; 2009 Apr; 276(8):2213-26. PubMed ID: 19302215
[TBL] [Abstract][Full Text] [Related]
18. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.
Oberst MD; Williams CA; Dickson RB; Johnson MD; Lin CY
J Biol Chem; 2003 Jul; 278(29):26773-9. PubMed ID: 12738778
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human matriptase by eglin c variants.
Désilets A; Longpré JM; Beaulieu ME; Leduc R
FEBS Lett; 2006 Apr; 580(9):2227-32. PubMed ID: 16566926
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
